S. R. Schill & Associates Abb Vie Inc. Transaction History

S. R. Schill & Associates

$119 Million
Q4 2024

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 15, 2024	SELL	$154.79 - $180.76 $420,719 - $491,305	-2,718 Reduced 44.83%	3,345 $573,000
Q1 2024 Apr 04, 2024	SELL	$159.82 - $182.1 $48,745 - $55,540	-305 Reduced 4.79%	6,063 $1.1 Million
Q4 2023 Jan 29, 2024	SELL	$137.6 - $154.97 $412 - $464	-3 Reduced 0.05%	6,368 $986,000
Q4 2022 Jan 25, 2023	SELL	$138.31 - $165.87 $20,469 - $24,548	-148 Reduced 2.27%	6,371 $0
Q3 2022 Oct 26, 2022	BUY	$134.21 - $153.93 $181,854 - $208,575	1,355 Added 26.24%	6,519 $875,000
Q1 2022 May 06, 2022	SELL	$131.98 - $163.75 $280,985 - $348,623	-2,129 Reduced 29.19%	5,164 $837,000
Q4 2021 Feb 14, 2022	SELL	$107.43 - $135.93 $105,066 - $132,939	-978 Reduced 11.82%	7,293 $987,000
Q3 2021 Oct 25, 2021	BUY	$106.4 - $120.78 $22,876 - $25,967	215 Added 2.67%	8,271 $892,000
Q1 2021 Apr 30, 2021	BUY	$102.3 - $112.62 $25,575 - $28,155	250 Added 3.2%	8,056 $872,000
Q4 2020 Jan 27, 2021	SELL	$80.49 - $108.67 $54,330 - $73,352	-675 Reduced 7.96%	7,806 $836,000
Q3 2020 Nov 18, 2020	BUY	$85.91 - $100.83 $164,861 - $193,492	1,919 Added 29.24%	8,481 $743,000
Q2 2020 Jul 30, 2020	BUY	$73.37 - $98.18 $207,490 - $277,653	2,828 Added 75.74%	6,562 $644,000
Q1 2020 May 04, 2020	SELL	$64.5 - $97.79 $1,096 - $1,662	-17 Reduced 0.45%	3,734 $284,000
Q4 2019 Feb 04, 2020	BUY	$72.13 - $90.25 $35,343 - $44,222	490 Added 15.03%	3,751 $332,000
Q3 2019 Oct 24, 2019	BUY	$62.98 - $75.72 $21,854 - $26,274	347 Added 11.91%	3,261 $247,000
Q3 2018 Oct 30, 2018	BUY	$88.91 - $98.84 $66,682 - $74,130	750 Added 34.66%	2,914 $276,000
Q2 2018 Jul 26, 2018	BUY	$89.78 - $106.23 $194,283 - $229,881	2,164 New	2,164 $200,000

Others Institutions Holding ABBV

# of Institutions

3,943

Shares Held

1.26B

Call Options Held

16.8M

Put Options Held

12.1M

View Full List

About AbbVie Inc.

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $337B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

More about ABBV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of S. R. Schill & Associates, based on Form 13F filings with the SEC.

News

Stay updated on S. R. Schill & Associates with notifications on news.

Account